Drug Trial Radar · NCT07270432
Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Jan 2026
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Ache Laboratorios Farmaceuticos S.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia
Conditions
- Prostatic Hyperplasia, Benign
Interventions
Product DNN.65.21.005Drug
One capsule every 24 hours
Combodart®Drug
One capsule every 24 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in International Prostate Symptom Score (IPSS)Time frame: 180 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.